GILD Insider Buying

The table below summarizes the most recent Gilead Sciences insider buying information — the latest buy being $999,150.00 by Olsen Per Wold on 2/6/2015, with links to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall Street, there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Gilead Sciences insider buys like these are important for investors to follow.
Gilead Sciences insider buying image
DateInsiderPriceAmount
2-6-2015
Insider Buy
Olsen Per Wold
Director
$99.92
CAGR »
$999,150.00
10,000 shares
2-28-2013
Insider Buy
Olsen Per Wold
Director
$43.05
CAGR »
$430,493.00
10,000 shares
2-22-2012
Insider Buy
Olsen Per Wold
Director
$44.00
CAGR »
$439,955.00
10,000 shares

Also See: Institutional Holders of GILD
Also See: SEC filings


Gilead Sciences Insider Purchase CAGR Analysis

GILD Performance Since Insider Purchase
Below we present the annualized performance delivered by Gilead Sciences stock since 2-6-2015 (the date of the most recent insider purchase). The performance of the investment from the time Gilead Sciences insider buying occurred is the ultimate test of whether insiders were right about GILD being a good buy.

Growth of $10,000.00
With Dividends Reinvested

Start date: 02/09/2015
End date: 09/04/2026
Start price/share: $96.90
End price/share: $151.00
Starting shares: 103.20
Ending shares: 150.41
Dividends reinvested/share: $29.37
Total return: 127.11%
Average Annual Total Return: 7.35%
Starting investment: $10,000.00
Ending investment: $22,722.70
Years: 11.57
 
Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/09/2015
End date: 09/04/2026
Start price/share: $96.90
End price/share: $151.00
Dividends collected/share: $29.37
Total return: 86.14%
Average Annual Total Return: 5.52%
Starting investment: $10,000.00
Ending investment: $18,622.77
Years: 11.57

Which GILD Insiders Report Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Gilead Sciences insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding GILD